Taysha Gene Therapies
55 articles about Taysha Gene Therapies
-
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
8/9/2022
Taysha Gene Therapies, Inc. announced that it will report its financial results for the second quarter ended June 30, 2022, and host a corporate update conference call and webcast on Thursday, August 11, 2022, at 8:00 AM Eastern Time.
-
Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
8/1/2022
Taysha Gene Therapies, Inc. today announced its participation in panel discussions at the BTIG Biotechnology Conference on August 8th and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10th.
-
Taysha Gene Therapies Announces Annual Stockholder MeetingThe Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET
6/13/2022
Taysha Gene Therapies, Inc. today announced that its annual stockholder meeting will be held on Friday, June 17, 2022 at 10 am ET via webcast.
-
Taysha Gene Therapies to Participate in Upcoming June 2022 Investor Conferences and Convention
6/2/2022
Taysha Gene Therapies, Inc. announced its participation in a fireside chat at the Jefferies Healthcare Conference, Goldman Sachs 43rd Annual Global Healthcare Conference, and JMP Securities Life Sciences Conference.
-
Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/16/2022
Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16
5/11/2022
Taysha Gene Therapies, Inc. today announced that it will report its financial results for the first quarter ended March 31, 2022, and host a corporate update conference call and webcast on Monday, May 16, 2022, at 8:00 AM Eastern Time.
-
Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy
5/10/2022
Taysha Gene Therapies, Inc. announced oral and poster presentations and a company-sponsored symposium at the upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy taking place in Washington, D.C. from May 16-19, 2022.
-
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)
5/3/2022
Taysha Gene Therapies, Inc. today announced that it has been granted orphan drug designation from the European Commission for TSHA-120, an intrathecally dosed AAV9 gene therapy currently in ongoing clinical evaluation for the treatment of giant axonal neuropathy (GAN).
-
Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit
4/25/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced oral presentations at the upcoming International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Symposium taking place in Nashville, Tennessee April 26 – 27, 2022, and the ASCEND Rett Syndrome National Summit.
-
Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
4/18/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced its participation in the upcoming panel and fireside chat at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Job cuts in biotech tend to occur during the end of a quarter, and the end of this first quarter is no different. Continue reading for news of four biotech companies making workforce layoffs this week.
-
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/31/2022
Taysha Gene Therapies, Inc. today reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update.
-
Taysha Gene Therapies announced that it will focus its efforts on clinical programs targeting Rett Syndrome and giant axonal neuropathy (GAN), resulting in a 35% reduction in its workforce.
-
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
3/29/2022
Taysha Gene Therapies, Inc. today announced the initiation of clinical development of TSHA-102 for the treatment of Rett syndrome under a recently approved Clinical Trial Application (CTA) by Health Canada.
-
Four companies, Pipeline Therapeutics, Prothena, Neuroplast, and Taysha Gene Therapies, announced launches of clinical trials in the CNS space.
-
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
3/24/2022
Taysha Gene Therapies, Inc. today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021, and host a corporate update conference call and webcast on Thursday, March 31, 2022, at 8:00 AM Eastern Time.
-
Taysha Gene Therapies to Participate in Upcoming April 2022 Investor Healthcare Conferences
3/23/2022
Taysha Gene Therapies, Inc. announced its participation in upcoming fireside chats at the Guggenheim Genomic Medicines and Rare Disease Day Conference and the 21st Annual Needham Virtual Healthcare Conference.
-
Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference
3/8/2022
Taysha Gene Therapies, Inc. announced its participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Monday, March 14, 2022, and Tuesday, March 15, 2022.
-
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
2/9/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the 18th Annual WORLD Symposium.